Loading…
Morepen Laboratories Limited has received clearance from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to conduct Bioequivalence (BE) studies for Resmetirom 60 mg, 80 mg, and 100 mg tablets.
Morepen Laboratories Limited has announced a change in the designation of Mr. Kushal Suri, a Senior Management Personnel.
Morepen Laboratories Limited's Finance Committee of the Board of Directors, in its meeting held on April 28, 2025, has approved the incorporation of a Wholly Owned Subsidiary of the Company in a Free Zone at Dubai, United Arab Emirates (UAE).
Morepen Laboratories Limited announced the launch of four new products in April 2025:
This launch is a strategic step to scale Morepen's finished dosages business, which is currently approximately ₹325 crore. The company aims to accelerate towards a target of ₹1,000 crore over the next five years, driven by deeper market penetration and an expanded portfolio. Morepen highlighted its position as India's #1 exporter of APIs for six global molecules, with a presence in 82 countries and an annual API capacity of 144 metric tons, leveraging its integrated capabilities.
Morepen Laboratories announced a significant expansion plan to strengthen its domestic formulation business. Key points:
Morepen Laboratories Limited has secured a term loan facility of ₹25 crores from Shinhan Bank, as approved on 29 Mar 25.
Key details of the loan agreement:
Morepen Laboratories Limited has declared the closure of its trading window commencing from 1 Apr 25. This decision is taken for the purpose of consideration and approval of the audited financial results for the quarter and financial year concluding on 31 Mar 25. The trading window will remain closed until 48 hours after the announcement of the said financial results.
Morepen Laboratories Limited (MOREPENLAB) announced the incorporation of a step-down subsidiary, Quick Med Private Limited, on 20 Mar 25.
Key details:
Morepen Laboratories Limited executed a Business Transfer Agreement (BTA) with its subsidiary, Morepen Medtech Limited, on 18 Mar 25 for the transfer of its Medical Devices Business via a slump sale as a going concern. This related party transaction, conducted at arm's length, is based on a valuation derived from Rule 11UAE of the Income Tax Rules, 1962. This execution follows an earlier intimation dated 14 Jan 25 regarding the same.
Morepen Laboratories Limited announced the launch of 'Empamore' on 17 Mar 25, a new treatment for Type 2 Diabetes Mellitus (T2DM), Heart Failure with Reduced Ejection Fraction (HFrEF), and Chronic Kidney Disease (CKD). Manufactured in USFDA-approved facilities, 'Empamore' aims to provide affordable, high-quality diabetes care, priced nearly 90% lower than existing brands, approximately 90% lower cost. The product range includes:
Morepen emphasizes its 40-year legacy in diabetes care, noting it has already installed 12.33 million glucometers and sold 1.65 billion blood glucose strips. 'Empamore' will be available nationwide and is packaged in convenient perforated strips for better patient adherence. Morepen Labs, established in 1984, has a global presence spanning 82 countries.